Immune checkpoints are hardwired into the immune system and are crucial for maintaining self-tolerance. Tumors can use these checkpoints to protect themselves from immune system attacks.
One such immune checkpoint is PD-1 (programmed cell death 1 protein), which binds to its ligand PD-L1 and inhibits immune cell activity, including T cell activity. By upregulating PD-L1, cancer cells can inhibit T cells that might otherwise attack. One strategy for cancer immunotherapy is to block this kind of negative feedback, thereby increasing anti-cancer T-cell activity. For the PD-1 checkpoint, cancer immunotherapeutics block either the PD-1 receptor, or the PD-L1 ligand.
The [https://www.nobelprize.org/prizes/medicine/2018/summary/ 2018 Nobel prize in Physiology or Medicine] was awarded to jointly to James Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. Phosphorylation sites were added based on information from PhosphoSitePlus (R), www.phosphosite.org.
Based on and figure 4B in the review by [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023/ Pardoll] and figure 1 in the review by [https://www.ncbi.nlm.nih.gov/pubmed/28990585 Sharpe and Pauken].
c58f89bdaa66https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-fusion-protein-amp-224parentid=Q15116; parentsymbol=PDCD1; site=CVPEQTEyATIVFPS; position=tyr248; sitegrpid=50293001; ptm=p; direction=u
parentid=P43403; parentsymbol=ZAP70; site=tsVyEsPysDPEELk; position=tyr319; sitegrpid=447587; ptm=p; direction=u
parentid=P43403; parentsymbol=ZAP70; site=VLLVNRHyAkISDFG; position=tyr474; sitegrpid=455368; ptm=p; direction=u
parentid=Q15116; parentsymbol=PDCD1; site=VPVFSVDyGELDFQW; position=tyr223; sitegrpid=450293000; ptm=p; direction=u
abce61ca128990585PubMedThe diverse functions of the PD1 inhibitory pathway.Nat Rev Immunol2018Sharpe AHPauken KEcancer pathwayPW:0000605Pathway Ontology29347993PubMedUpdated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.J Immunother Cancer2018Kaufman HLRussell JSHamid OBhatia STerheyden PD'Angelo SPShih KCLebbé CMilella MBrownell ILewis KDLorch JHvon Heydebreck AHennessy MNghiem PcancerDOID:162Disease30345906PubMedAtezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med2018Schmid PAdams SRugo HSSchneeweiss ABarrios CHIwata HDiéras VHegg RIm SAShaw Wright GHenschel VMolinero LChui SYFunke RHusain AWiner EPLoi SEmens LA30511409PubMedImmune checkpoint blockade opens a new way to cancer immunotherapy.J Cell Physiol2019Sadreddini SBaradaran BAghebati-Maleki AShanehbandi DFotouhi AAghebati-Maleki L22437870PubMedThe blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer2012Pardoll DM28643244PubMedDurvalumab: First Global Approval.Drugs2017Syed YYadaptive immune response pathwayPW:0000235Pathway Ontology25514926PubMedPhosphoSitePlus, 2014: mutations, PTMs and recalibrations.Nucleic Acids Res2015Hornbeck PVZhang BMurray BKornhauser JMLatham VSkrzypek ET cellCL:0000084Cell Type